of the
Follow our MOtM once a month to see new compounds, recent examples of their applications,
potential breakthroughs, and much more.
With the “low hanging fruit” of early drug discovery gone, pharmaceutical companies are increasingly turning to developing high-throughput synthetic platforms capable of greatly shortening the design−make−test cycle of new drugs…
To form stable protein degrading complexes, optimal linkers are required. Although most PROTAC structures contained alkyl and PEG motifs, more recently linear linkers have been replaced by rigid linkers
Highly enantiomerically enriched dihydrohydroquinolines were prepared in two steps from quinoline. Addition of aryllithiums to quinoline with tert-butoxycarbonyl (Boc) protection gave...
Take advantage of LCC’s 3Discovery platform to progress from Ro3 fragment space into Ro4 lead-like space.
Expedite your drug discovery by accessing our new range of novel, 3D-rich, chirally-pure synthons, designed to expedite your drug discovery.
With their increased prevalence in FDA approved drugs, the requirement for chiral N-heterocycles is also expanding. However, effective methods for their synthesis from simple starting materials are scarce…
Recently, the use of covalent fragments as electrophilic probes has seen a revitalized interest within drug discovery. As a result, LCC were keen to make covalent fragments readily available to the drug discovery community via…
LCC’s October MotM showcases the work done in collaboration with Anagenex to validate a representative set of LCC’s DEL Synthons for on-DNA synthesis. Download the pdf below for more details!
Our September edition of Molecules of the Month is focused on an excellent paper published this week by Tao et al., titled ‘Targeted Protein Degradation by Electrophilic PROTACs that Stereo selectively and Site-Specifically Engage DCAF1’.1 …
Fragment-based drug discovery (FBLD) has proven to be an increasingly important tool for discovering lead compounds, through using both biochemical and biophysical methods to detect very small molecules. Thanks to the success of FBLD…
In keeping with our aim to continue looking for new ways in which we can play a part in the discovery of drugs, LCC are excited to announce that our first focused VL is ready to be screened! We have chosen to base this library on…
